Literature DB >> 7536739

Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases.

A Siri1, V Knäuper, N Veirana, F Caocci, G Murphy, L Zardi.   

Abstract

Two major tenascin-C (TN-C) isoforms are generated by the alternative splicing of the pre-mRNA. The large isoform contains seven extra type three repeats that, by contrast, are omitted in the small TN-C isoform. The large TN-C isoform is mainly expressed at the onset of cellular processes that entail active cell migration, proliferation, or tissue remodeling such as occur in neoplasia, wound healing, and during development. Thus, the large TN-C isoform seems to be a specific component of the provisional extracellular matrix. Here we have studied the degradation of the large and small TN-C isoforms by matrix metalloproteinases (MMPs) 2, 3, 7, and 9. Among these proteolytic enzymes only MMP-7 can degrade the small TN-C isoform removing the NH2-terminal knob. The large TN-C isoform shows the same MMP-7-sensitive site adjacent to the NH2-terminal sequence, but is further degraded in the splicing area where three fibronectin-like type III repeats are completely digested. Moreover, the large TN-C isoform is degraded by MMP-2 and MMP-3 which completely digest a single type III repeat inside the splicing area. By contrast, the large TN-C isoform is resistant to MMP-9 digestion. The results show that the presence of the spliced sequence introduces new protease-sensitive sites in the large TN-C isoform.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536739     DOI: 10.1074/jbc.270.15.8650

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

2.  Neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, interacts with pleiotrophin, a heparin-binding growth factor.

Authors:  Keiko Nakanishi; Yoshihito Tokita; Sachiko Aono; Michiru Ida; Fumiko Matsui; Yujiro Higashi; Atsuhiko Oohira
Journal:  Neurochem Res       Date:  2010-04-06       Impact factor: 3.996

Review 3.  Tenascins and the importance of adhesion modulation.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

4.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

5.  Tenascin-C and human tendon degeneration.

Authors:  G P Riley; R L Harrall; T E Cawston; B L Hazleman; E J Mackie
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

6.  Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Lisandra E de Castro Brás; Kevin Hakala; Susan T Weintraub; Merry L Lindsey
Journal:  Methods Mol Biol       Date:  2013

7.  Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome.

Authors:  Nobuo Sakamoto; Yasuto Hoshino; Tomofumi Misaka; Hiroyuki Mizukami; Satoshi Suzuki; Koichi Sugimoto; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-ichi Saitoh; Yasuchika Takeishi
Journal:  Heart Vessels       Date:  2013-03-27       Impact factor: 2.037

8.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

9.  Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids.

Authors:  Kanokkarn Phromnoi; Supachai Yodkeeree; Songyot Anuchapreeda; Pornngarm Limtrakul
Journal:  Acta Pharmacol Sin       Date:  2009-07-20       Impact factor: 6.150

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.